Syncromune, Inc.Amended

Biotechnology · FORT LAUDERDALE, FL

BiotechnologySEC Form D

Syncromune, Inc. filed a Form D with the U.S. Securities and Exchange Commission on May 11, 2026, reporting $144,828,791 raised.

Incorporated in Delaware and based in FORT LAUDERDALE, FL, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Syncromune, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Charles J. LinkExecutive Officer · Director
  • Eamonn HobbsExecutive Officer · Director
  • Joseph GerardiExecutive Officer
  • Agustin GagoExecutive Officer
  • Joseph C. MaroonDirector
  • Douglas G. WatsonDirector
  • Jeffrey L. ClelandDirector
  • Norman SchwartzDirector
  • Kerri-Ann MillarExecutive Officer
  • Stephen DaleExecutive Officer

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$1.6MRaised

Biolexis Therapeutics Inc.

BiotechnologyLEHI, UT
May 20, 2026View SEC Form D
Syncromune, Inc. raised $144.8M — SEC Form D